Clinton to Work With Congress on Drug Pricing If Elected: Beacon

If Hillary Clinton becomes president and Democrats control the Senate, they might take steps toward limiting drug pricing "shortly after the start of a new administration," Beacon Policy Advisors analysts say in research note.

  • Policy solutions may include enhanced FTC oversight of anti-competitive drug pricing strategies and implementation of drug pricing transparency requirements, analysts say
  • Analysts say three bills, bipartisan "pay-for-delay" measure S. 2019, CREATES Act, and Sen. Susan Collins’ bill to increase competition in the generic marketplace, "will likely form the basis for reforms undertaken next year shortly after the start of a new administration"
  • Note: Mylan, Valeant are among cos. drawing lawmakers’ ire over increased drug prices